Eicosanoids and the Immunology of Cancer

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 1994 Dec 1

PMID 7712595

Citations 14

Authors

M R Young

Affiliations

Soon will be listed here.

Abstract

Studies in both cancer patients and in animal tumor models have shown that immune defenses can mediate destruction of tumor, but these defenses are often functioning at a suppressed or suboptimal level. Frequently, prostaglandins, mainly PGE2, have been implicated in this tumor-associated subversion of immune function, with immune reactivities to tumor typically being enhanced by prostaglandin synthesis inhibitor. Both the tumor and tumor-induced host immune suppressive macrophages have the capacity to suppress immune functions through their production of PGE2. Although the inhibitory functions have been more widely studied, recent evaluations of the effects of PGE2 have led to the surprising realization that not all of the PGE2's effects are inhibitory to immune function. Summarized below are some of the well characterized inhibitory effects of PGE2, as well as the lesser studied stimulatory effects of PGE2 toward the effector cells that are considered to be important in the immune defense against cancer.

Citing Articles

Eicosanoids in Cancer: New Roles in Immunoregulation.

Johnson A, Kleczko E, Nemenoff R Front Pharmacol. 2020; 11:595498.

PMID: 33364964 PMC: 7751756. DOI: 10.3389/fphar.2020.595498.

Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction.

Faber J, Uitdehaag M, Spaander M, van Steenbergen-Langeveld S, Vos P, Berkhout M J Cachexia Sarcopenia Muscle. 2015; 6(1):32-44.

PMID: 26136410 PMC: 4435095. DOI: 10.1002/jcsm.12009.

Premalignant lesions skew spleen cell responses to immune modulation by adipocytes.

Vielma S, Klein R, Levingston C, Young M Anticancer Res. 2013; 33(5):1809-18.

PMID: 23645725 PMC: 5925418.

Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia.

Faber J, Vos P, Kegler D, van Norren K, Argiles J, Laviano A Br J Cancer. 2008; 99(12):2029-36.

PMID: 19018259 PMC: 2607220. DOI: 10.1038/sj.bjc.6604785.

Enhancement of nitric oxide release in mouse inflammatory macrophages co-cultivated with tumor cells of a different origin.

Calorini L, Bianchini F, Mannini A, Mugnai G, Ruggieri S Clin Exp Metastasis. 2005; 22(5):413-9.

PMID: 16283484 DOI: 10.1007/s10585-005-1263-x.

References

Fidler I . Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis. Res Immunol. 1992; 143(2):199-204. DOI: 10.1016/s0923-2494(92)80166-i. View

Gately M, Desai B, Wolitzky A, Quinn P, Dwyer C, Podlaski F . Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol. 1991; 147(3):874-82. View

Fazio M, Calabrese F, Coluccia C, Giacomasso S, Casadio C, Mancuso M . The LMI test in colon, breast and lung cancer long survivors. Panminerva Med. 1992; 34(2):60-4. View

Farinas M, Rodriguez-Valverde V, Zarrabeitia M, Sanz-Ortiz J . Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer. Cancer. 1991; 68(6):1279-84. DOI: 10.1002/1097-0142(19910915)68:6<1279::aid-cncr2820680617>3.0.co;2-y. View

Young M, Lozano Y, Djorjevic A, MAIER G . Protein phosphatases limit tumor motility. Int J Cancer. 1993; 54(6):1036-41. DOI: 10.1002/ijc.2910540629. View

Rigas B, Goldman I, Levine L . Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993; 122(5):518-23. View

Young M, Young M, Kim K . Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2. Cancer Res. 1988; 48(23):6826-31. View

Young M, Hoover C . Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma. J Natl Cancer Inst. 1986; 77(2):425-9. View

Bukowski R, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J . Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res. 1991; 51(16):4199-205. View

10.

Cox F, Liew F . T-cell subsets and cytokines in parasitic infections. Immunol Today. 1992; 13(11):445-8. DOI: 10.1016/0167-5699(92)90072-F. View

11.

Sunder-Plassmann R, Majdic O, Knapp W, Holter W . In vitro and in vivo activated T cells display increased sensitivity to PGE2. Cell Immunol. 1991; 138(2):289-99. DOI: 10.1016/0008-8749(91)90154-4. View

12.

Yano T, Ishida T, Yoshino I, Murata M, Yasumoto K, Kimura G . A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects. Biotherapy. 1991; 3(3):245-51. DOI: 10.1007/BF02171688. View

13.

Vaillier D, Daculsi R, Gualde N, Bezian J . Effect of LTB4 on the inhibition of natural cytotoxic activity by PGE2. Cell Immunol. 1992; 139(1):248-58. DOI: 10.1016/0008-8749(92)90117-8. View

14.

Stewart T, HOLLINSHEAD A, Raman S . Tumour dormancy: initiation, maintenance and termination in animals and humans. Can J Surg. 1991; 34(4):321-5. View

15.

Lapointe H, Lampe H, Banerjee D . Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses. Otolaryngol Head Neck Surg. 1992; 106(2):149-58. DOI: 10.1177/019459989210600205. View

16.

Maas R, Dullens H, Den Otter W . Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother. 1993; 36(3):141-8. PMC: 11038683. DOI: 10.1007/BF01741084. View

17.

Walker T, Yurochko A, Burger C, Elgert K . Cytokines and suppressor macrophages cause tumor-bearing host CD8+ T cells to suppress recognition of allogeneic and syngeneic MHC class II molecules. J Leukoc Biol. 1992; 52(6):661-9. DOI: 10.1002/jlb.52.6.661. View

18.

Sato N, Fujisawa N, Kato A, Maeda Y, Yamamoto Y . Tumor dormancy and the effect of selected drugs on the tumor-dormant state. Lab Anim Sci. 1992; 42(6):555-60. View

19.

Scudeletti M, Filaci G, Imro M, Motta G, Di Gaetano M, Pierri I . Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer. Cancer Immunol Immunother. 1993; 37(2):119-24. PMC: 11038392. DOI: 10.1007/BF01517044. View

20.

Yoshizawa H, Chang A, Shu S . Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res. 1992; 52(5):1129-36. View